GlassScriptPhysician profile
Jordan N Baker-Horn
NPI 1194953976
$8,456.09
in general payments reported to CMS, 2019-2025
37 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $224 · 2021: $1,308 · 2022: $1,674 · 2023: $1,350 · 2024: $1,740 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,583.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,063.12 | 2019-2025 | Ubrelvy, Viberzi, Linzess |
| Novo Nordisk INC | $1,394.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,037.68 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $676.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $640.31 | 2019-2025 | |
| Astellas Pharma US INC | $287.97 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $284.52 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Xeris Pharmaceuticals, INC. | $210.79 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.34 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $179.82 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $165.36 | 2022 | |
| Merck Sharp & Dohme LLC | $124.64 | 2020-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Exact Sciences Corporation | $115.68 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $113.25 | 2019-2022 | |
| Glaxosmithkline, LLC. | $97.33 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Baker-Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.